Endocrine Abstracts

The role of the androgen receptor (AR) in the progression of prostate cancer (PCa) is well established. Competitive inhibition of the AR ligand binding domain (LBD) has been the staple of antiandrogen therapies employed to combat the disease in recent years. However their efficacy has often been limited by the emergence of resistance, mediated through point mutations and receptor truncations. As a result the prognosis for patients with malignant castrate resistant disease rema...